Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases

The liver is a major metabolic organ that performs many essential biological functions such as detoxification and the synthesis of proteins and biochemicals necessary for digestion and growth. Any disruption in normal liver function can lead to the development of more severe liver disorders. Overall...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Biology
المؤلفون الرئيسيون:	Madan Kumar Arumugam, Thiyagarajan Gopal, Rakhee Rathnam Kalari Kandy, Lokesh Kumar Boopathy, Sathish Kumar Perumal, Murali Ganesan, Karuna Rasineni, Terrence M. Donohue, Natalia A. Osna, Kusum K. Kharbanda
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2023-10-01
الموضوعات:	mitochondria metabolic-dysfunction-associated steatotic liver disease alcohol-associated liver disease liver hepatocytes steatotic liver diseases
الوصول للمادة أونلاين:	https://www.mdpi.com/2079-7737/12/10/1311

مواد مشابهة

Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases
حسب: Sathish Kumar Perumal, وآخرون
منشور في: (2025-03-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
حسب: K. L. Raikhelson, وآخرون
منشور في: (2024-05-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
حسب: Gi-Ae Kim, وآخرون
منشور في: (2023-10-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
حسب: Byeong Geun Song, وآخرون
منشور في: (2024-03-01)

Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study
حسب: Qiaoling Wu, وآخرون
منشور في: (2025-01-01)

Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study
حسب: Yebei Liang, وآخرون
منشور في: (2025-02-01)

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
حسب: Andrea Caddeo, وآخرون
منشور في: (2025-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
حسب: Yu-Ming Cheng, وآخرون
منشور في: (2024-12-01)

Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
حسب: Jesse Pustjens, وآخرون
منشور في: (2024-12-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
حسب: Chavdar S. Pavlov, وآخرون
منشور في: (2024-05-01)

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
حسب: Yangyue Zhang, وآخرون
منشور في: (2025-01-01)

Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
حسب: Chuheng Gou, وآخرون
منشور في: (2025-12-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
حسب: Yu-Ming Cheng, وآخرون
منشور في: (2025-04-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
حسب: Yeo-Wool Kang, وآخرون
منشور في: (2024-11-01)

Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
حسب: Maksym Zhaivoronok, وآخرون
منشور في: (2025-03-01)

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease
حسب: Xiongcai Feng, وآخرون
منشور في: (2023-11-01)

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
حسب: Maria Gabriela Fernandes DEZAN, وآخرون
منشور في: (2025-09-01)

Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
حسب: Amani Elshaer, وآخرون
منشور في: (2024-12-01)

Cirrhosis epidemiology in Denmark 1998–2022, and 2030 forecast
حسب: Linda Skibsted Kornerup, وآخرون
منشور في: (2025-05-01)

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
حسب: Won Sohn, وآخرون
منشور في: (2025-02-01)

Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region
حسب: Pojsakorn Danpanichkul, وآخرون
منشور في: (2024-08-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
حسب: Umasankari S., وآخرون
منشور في: (2024-12-01)

Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease
حسب: Thaninee Prasoppokakorn, وآخرون
منشور في: (2024-12-01)

Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease
حسب: Zhikun Dai, وآخرون
منشور في: (2025-02-01)

Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
حسب: Yuting Huang, وآخرون
منشور في: (2024-12-01)

Treatment of HCV infection in patients with steatotic liver disease
حسب: Robert Flisiak, وآخرون
منشور في: (2024-07-01)

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease
حسب: Yuri Cho
منشور في: (2024-11-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
حسب: Michihiro Iwaki, وآخرون
منشور في: (2024-04-01)

Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
حسب: Jiaxin Chen, وآخرون
منشور في: (2024-06-01)

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
حسب: Woo-Young Shin, وآخرون
منشور في: (2025-04-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
حسب: Katharina Staufer, وآخرون
منشور في: (2023-07-01)

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
حسب: Haixiang Zheng, وآخرون
منشور في: (2024-09-01)

Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
حسب: Francisco Aguirre, وآخرون
منشور في: (2025-07-01)

Association between periodontitis and mortality in participants with metabolic dysfunction-associated steatotic liver disease: results from NHANES
حسب: Zhaofu Zhang, وآخرون
منشور في: (2025-04-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
حسب: Shyam Patel, وآخرون
منشور في: (2025-01-01)

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
حسب: Seogsong Jeong, وآخرون
منشور في: (2025-04-01)

A Pathogenic Role of Non-Parenchymal Liver Cells in Alcohol-Associated Liver Disease of Infectious and Non-Infectious Origin
حسب: Kusum K. Kharbanda, وآخرون
منشور في: (2023-02-01)

Chronic liver disease is an important risk factor for worse outcomes in acute pancreatitis: a systematic review and meta-analysis
حسب: Jakub Hoferica, وآخرون
منشور في: (2024-07-01)

ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population
حسب: Ville Männistö, وآخرون
منشور في: (2024-10-01)

Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma
حسب: Chen P, وآخرون
منشور في: (2024-03-01)